Skip to content
Vesalius Therapeutics

Our Leadership

Christopher P. Austin, MD
Christopher P. Austin, MD
CEO
Ben Munoz, PhD
Ben Munoz, PhD
SVP, Head of Drug Discovery
David Twomey
David Twomey

VP, Informatics and Data Science

Board of Directors

Doug Cole, MD
Doug Cole, MD

Managing Partner, Flagship Pioneering
Founder Vesalius

Christopher P. Austin, MD
Christopher P. Austin, MD
CEO

Scientific Advisory Board

  • Lee Rubin

    Professor of Stem Cell and Regenerative Biology, Harvard University, and Co-Director, Neuroscience Program, Harvard Stem Cell Institute

  • Paola Arlotta

    Chair, Department of Stem Cell & Regenerative Biology, Harvard University

  • Percy Carter

    Chief Scientific Officer, Blueprint Medicines

  • John A. Todd

    Director, Wellcome Centre for Human Genetics, University of Oxford

  • Wendy Chung

    Professor of Pediatrics in Medicine, Columbia University

  • Tanya Fischer

    Vice President, CNS Development, Alnylam Pharmaceuticals

  • Justin Ichida

    Associate Professor of Stem Cell Biology and Regenerative Medicine, University of Southern California

  • 08/01/2022

    Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs

    Biotech investors look at hundreds of startups each year, trying to find the best new companies. Here are the privately held, venture-backed businesses they think will take off.

    Read More
  • 03/01/2022

    Flagship Pioneering Unveils Vesalius Therapeutics to Revolutionize the Treatment of the Diseases that Drive Ninety Percent of Human Illness

    Flagship Pioneering today unveiled Vesalius Therapeutics, a company focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness. Flagship initially committed $75 million to support the development of Vesalius’ platform and initial pipeline of new medicines.

    Read More